Immix Biopharma, Inc.

IMMX

US45258H1068

Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 11:56:18 2024-05-01 am EDT			5-day change	1st Jan Change
2.085 ^USD	-3.92%		+0.23%	-69.15%

Apr. 29	Immix Biopharma Gets Orphan Drug Label in Europe For Multiple Myeloma Treatment	MT
Apr. 18	Immix Biopharma on Track to Dose First Patients with AL Amyloidosis Therapy by Mid-Year	MT

Immix Biopharma Completes 3rd NXC-201 Engineering Batch at its U.S. CAR-T Manufacturing Site

October 16, 2023 at 09:05 am EDT

Immix Biopharma, Inc. announced the successful completion of its 3rd engineering batch of BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy NXC-201 at its U.S. manufacturing site. NXC-201 will be manufactured for each individual patient using the patient?s own T cells at its cellular immunotherapy manufacturing facility in California.

Latest news about Immix Biopharma, Inc.

Immix Biopharma Gets Orphan Drug Label in Europe For Multiple Myeloma Treatment	Apr. 29	MT
Immix Biopharma on Track to Dose First Patients with AL Amyloidosis Therapy by Mid-Year	Apr. 18	MT
Immix Biopharma, Inc. Announces on Track to Dose NXC-201 Patients in United States	Apr. 18	CI
Immix Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 29	CI
Immix Biopharma, Inc. Announces Major Comprehensive Cancer Center as Lead Site for NXC-201 Al Amyloidosis Clinical Trial	Mar. 20	CI
Immix Biopharma Prices $15 Million Stock Offering	Feb. 06	MT
Immix Biopharma Proposes Stock Offering; Shares Slump	Feb. 05	MT
Immix Biopharma, Inc. Announces New Clinical Data from Its Phase 1b/2a NEXICART-1	Dec. 11	CI
Immix Biopharma, Inc. to Host KOL Event to Discuss Its BCMA-Targeted CAR-T Cell Therapy Candidate NXC-201 for Relapsed/Refractory AL Amyloidosis	Nov. 22	CI
Immix Biopharma Says FDA Clears Investigational New Drug Application for NXC-201; Shares Fall	Nov. 21	MT
Immix Biopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
Immix Biopharma Presents NXC-201 Data at 65th American Society of Hematology Annual Meeting in 9 Relapsed/Refractory AL Amyloidosis Patients	Nov. 06	CI
Immix Biopharma Completes 3rd NXC-201 Engineering Batch at its U.S. CAR-T Manufacturing Site	23-10-16	CI
Immix Biopharma, Inc. Announces Complete Response in 9Th Relapsed/Refractory AL Amyloidosis Patient in NXC-201 Clinical Trial At IMS 20Th Annual Meeting	23-10-03	CI
Top Midday Gainers	23-10-02	MT
Immix Biopharma Inc. Announces 72-Patient NXC-201 Clinical Data at the IMS 20th Annual Meeting, 95% Overall Response Rate in Multiple Myeloma	23-10-02	CI
Immix Biopharma Files Registration Statement on Behalf of Selling Stockholder	23-09-26	MT
Immix Biopharma Gets FDA Orphan Drug Label For NXC-201 to Treat Amyloid Light Chain Amyloidosis	23-09-21	MT
Sector Update: Health Care Stocks Rising Late Afternoon	23-08-23	MT
Sector Update: Health Care	23-08-23	MT
Immix Biopharma Says US FDA Grants Orphan Drug Designation for NXC-201 to Treat Multiple Myeloma	23-08-23	MT
Immix Biopharma Shares Rise 11% Premarket on Key FDA Designation	23-08-23	DJ
Immix Biopharma, Inc Announces U.S. Food and Drug Administration Approves Orphan Drug Designation for Immix Biopharma NXC-201 as a Treatment for Multiple Myeloma	23-08-23	CI
Immix Biopharma, Inc. Appoints Yekaterina Chudnovsky as Member of the Board	23-08-22	CI
Immix Biopharma, Inc. announced that it has received $9.999998 million in funding	23-08-21	CI

Chart Immix Biopharma, Inc.

Duration

Period

More charts

Company Profile

Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the application of chimeric antigen receptor cell therapy (CAR- T) in light chain (AL) Amyloidosis and autoimmune disease. The Company's lead cell therapy asset is CAR-T NXC-201 for autoimmune disease, relapsed/refractory AL Amyloidosis, and relapsed/refractory multiple myeloma, which is being evaluated in its ongoing Phase Ib/IIa NEXICART-1 (NCT04720313) clinical trial. Its tissue specific therapeutic IMX-110 is in clinical trials as a monotherapy, and in combination with tislelizumab (BeiGene anti-PD-1 - IMMINENT-01 NCT05840835) for advanced solid tumors, such as relapsed/refractory colorectal cancer (CRC). IMX-110 in Phase Ib/IIa clinical trials, is a Tissue-Specific Therapeutic with TME Normalization, a technology that the Company is developing initially for mCRC and Soft Tissue Sarcoma (STS).

Sector

Pharmaceuticals

Calendar

2024-05-10 - American Society of Gene & Cell Therapy Meeting - HBI0101

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

2.17 USD

Average target price

14 USD

Spread / Average Target

+545.16%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
IMMIX BIOPHARMA, INC.	-69.15%	57.28M
CSL LIMITED	-4.24%	86.85B
SAMSUNG BIOLOGICS CO.,LTD.	+2.76%	40.16B
BIOGEN INC.	-16.39%	31.28B
UCB	+57.86%	25.27B
BIOMARIN PHARMACEUTICAL INC.	-15.28%	15.33B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-9.12%	11.96B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-42.56%	11.61B
SWEDISH ORPHAN BIOVITRUM AB	+6.89%	8.83B
INNOVENT BIOLOGICS, INC.	-10.53%	7.94B

Biopharmaceuticals

Immix Biopharma, Inc.

Equities

IMMX

US45258H1068

Pharmaceuticals

Immix Biopharma Completes 3rd NXC-201 Engineering Batch at its U.S. CAR-T Manufacturing Site

Latest news about Immix Biopharma, Inc.

Chart Immix Biopharma, Inc.

Company Profile

Income Statement Evolution

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Biopharmaceuticals